Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Iohexol, a new water-soluble nonionic contrast medium, was evaluated in clinical trials in Europe and North America for lumbar, thoracic, and cervical myelography using direct C1-2 or lumbar puncture. Iohexol was administered at 180, 240, or 300 mg I/ml to 677 adult patients for visualization of the lumbar subarachnoid space, and to 368 adult patients for evaluation of the cervical area. Compared with metrizamide, use of iohexol resulted in equivalent opacification but significantly reduced patient morbidity (headache, nausea, vomiting, dizziness). No epileptogenic activity was recorded in over 370 patients receiving iohexol. No mental or psycho-organic syndrome manifestations were observed in any of the 1,045 patients receiving iohexol. Adverse reactions occurring after iohexol injection were not related to the concentration or site used or to total dose administered. Iohexol has, thus far, proven superior to metrizamide for myelography.
 ...
PMID:Iohexol: summary of North American and European clinical trials in adult lumbar, thoracic, and cervical myelography with a new nonionic contrast medium. 388 16

An open, non comparative study of cervical myelography in 68 adult patients using iohexol (Omnipaque) containing 300 mg I/ml is reported. Satisfactory visualisation was achieved in all cases. Minor adverse effects occurred in 13 patients (19%); they were headache (8), neck or back pain (3), vomiting (3), nausea (1), dizziness (1) and nystagmus (1) and were of minor degree in most and moderate in a few, lasting more than 24 hours in only one patient. EEG performed in 39 patients before and 24 h after the myelogram showed no seizure activity or significant change. Iohexol is a very satisfactory drug for all types of myelography.
 ...
PMID:Cervical myelography with iohexol. 647 36

We randomised 86 patients undergoing intra-arterial cerebral digital subtraction angiography (IADSA) to receive iodixanol (Visipaque; Nycomed, Oslo, Norway) 150 mgI/ml or iohexol (Omnipaque; Nycomed) 140 mgI/ml. The efficacy and safety of these two contrast media were compared: efficacy by evaluating the diagnostic information and radiographic density yielded by the angiograms, safety by recording all discomfort connected with the injections, and all adverse events up to 24 h after the investigation. Diagnostic information was optimal in all patients and the overall radiographic density optimal in all but one (iohexol) (P = 0.49). A feeling of warmth, the only discomfort reported, was experienced by 43% and 54% of patients receiving iodixanol and iohexol, respectively (P = 0.26). Two patients in the iodixanol group and five in the iohexol group reported one adverse event (nausea, dizziness, visual disturbance or paraesthesiae) (P = 0.30); all were of mild severity except for one moderate adverse event in each group. Iodixanol 150 mgI/ml and iohexol 140 mgI/ml were demonstrated to be suitable for IADSA, with no clinically or statistically significant differences in efficacy, discomfort or adverse events.
 ...
PMID:Iodixanol in intra-arterial cerebral digital subtraction angiography: a comparison with iohexol. 857 43